CN1154506C - 预防或治疗过敏的方法 - Google Patents
预防或治疗过敏的方法 Download PDFInfo
- Publication number
- CN1154506C CN1154506C CNB961947527A CN96194752A CN1154506C CN 1154506 C CN1154506 C CN 1154506C CN B961947527 A CNB961947527 A CN B961947527A CN 96194752 A CN96194752 A CN 96194752A CN 1154506 C CN1154506 C CN 1154506C
- Authority
- CN
- China
- Prior art keywords
- prescription
- preparation
- lactobacillus rhamnosus
- atcc
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 13
- 230000007815 allergy Effects 0.000 title abstract description 3
- 241000894006 Bacteria Species 0.000 claims abstract description 21
- 239000003531 protein hydrolysate Substances 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 108010009736 Protein Hydrolysates Proteins 0.000 claims abstract description 18
- 208000009793 Milk Hypersensitivity Diseases 0.000 claims abstract description 10
- 201000010859 Milk allergy Diseases 0.000 claims abstract description 10
- 230000004888 barrier function Effects 0.000 claims abstract description 9
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 claims description 41
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 claims description 41
- 230000007062 hydrolysis Effects 0.000 claims description 35
- 238000006460 hydrolysis reaction Methods 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 33
- 230000001580 bacterial effect Effects 0.000 claims description 27
- 229940088598 enzyme Drugs 0.000 claims description 21
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 208000003455 anaphylaxis Diseases 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 17
- 230000017854 proteolysis Effects 0.000 claims description 17
- 102000004142 Trypsin Human genes 0.000 claims description 16
- 108090000631 Trypsin Proteins 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 16
- 239000012588 trypsin Substances 0.000 claims description 16
- 102000057297 Pepsin A Human genes 0.000 claims description 15
- 108090000284 Pepsin A Proteins 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 229940111202 pepsin Drugs 0.000 claims description 15
- 230000036783 anaphylactic response Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 230000003301 hydrolyzing effect Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 208000030961 allergic reaction Diseases 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 230000001900 immune effect Effects 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 abstract description 21
- 229940039696 lactobacillus Drugs 0.000 abstract description 20
- 230000002496 gastric effect Effects 0.000 abstract description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 5
- 206010070834 Sensitisation Diseases 0.000 abstract description 3
- 230000008313 sensitization Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 239000013566 allergen Substances 0.000 abstract 1
- 235000020247 cow milk Nutrition 0.000 abstract 1
- 201000005356 cow milk allergy Diseases 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 235000020883 elimination diet Nutrition 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004046 hyporesponsiveness Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 abstract 1
- 230000000529 probiotic effect Effects 0.000 abstract 1
- 235000018291 probiotics Nutrition 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 239000005018 casein Substances 0.000 description 46
- 102000011632 Caseins Human genes 0.000 description 19
- 108010076119 Caseins Proteins 0.000 description 19
- 230000000844 anti-bacterial effect Effects 0.000 description 19
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 19
- 235000021240 caseins Nutrition 0.000 description 19
- 235000013336 milk Nutrition 0.000 description 19
- 239000008267 milk Substances 0.000 description 19
- 210000004080 milk Anatomy 0.000 description 19
- 239000000047 product Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 14
- 206010012438 Dermatitis atopic Diseases 0.000 description 12
- 201000008937 atopic dermatitis Diseases 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000000813 microbial effect Effects 0.000 description 12
- 102000004388 Interleukin-4 Human genes 0.000 description 11
- 108090000978 Interleukin-4 Proteins 0.000 description 11
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 11
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 11
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 11
- 235000013350 formula milk Nutrition 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 239000000413 hydrolysate Substances 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000012531 culture fluid Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000004365 Protease Substances 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 206010003645 Atopy Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002052 anaphylactic effect Effects 0.000 description 3
- 230000001475 anti-trypsic effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000013586 microbial product Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000348346 Suta Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
- A23J3/344—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins of casein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及抑制遭受食物过敏的病人的食物引发的过敏反应的方法和途径。本发明尤其提供了制备一种抑制过敏反应和提高消化道免疫屏障物的蛋白质水解产物配方的方法，和预防或治疗过敏，尤其是婴儿的牛奶过敏的方法，这是通过用从胃肠道中获得的合适的益生菌(probiotic bacteria)，尤其是乳杆菌，来强化牛奶消食而进行的。而且，施用一种由胃肠细菌免疫反应改性的过敏原的片断可以将敏感反应转变为全身性的反应低下。用于本发明的一种优选细菌是乳杆菌GG(ATCC 53103)。
Description
本发明涉及对遭受食物过敏的病人抑制由食物引发的过敏反应的方法和途径。此发明尤其提供了预防或治疗过敏症，特别是婴儿的牛奶过敏症的方法。本发明也涉及发展用于带有消化道屏障功能损害的过敏婴儿的特殊配方。
牛奶过敏症(cmA)被定义为对牛奶蛋白的一种免疫介异的不良反应。本选择的治疗是彻底除去牛奶抗原。对于有cmA的婴儿，当不能获得人奶时，有必要用一种替代处方。基于从牛奶中获得的乳清或酪蛋白的水解处方，被用于来提供足够的营养并有减少的抗原负荷。对牛奶的初步热处理主要影响蛋白的构象，并且易于它们的水解。用胃肠白酶，胰蛋白酶，胰提取物和肠粘膜提取物的随后的酶水解导致顺序抗原决定基的逐渐破坏和将处方精制为最少的抗原和过敏形式。
大多数情况下，可安全地采用彻底水解的牛奶衍生的处方，这些有效且在临床和代谢上有好的耐受性。但是，酶水解不一定使处方非过敏，因为最佳的水解程度不知且在水解物中可以测到微量的最初蛋白。因此要小心地将这些替代物引入有牛奶过敏症的小孩。
通过除去抗原来控制过敏性炎症的方法不能令人满意，尤其是对患有多种食物过敏的患者(Sampson等，1992)。这些患者经常表现出增强的肠渗透性和肠防御屏障的机能异常(Majamaa等，1996，Majamaa和Isolauri，1996)。这增大了生长紊乱和对多种食物敏化的危险性。迫切需要有新方法来治疗牛奶过敏以提高cmA中替代物处方。
肠抗原处理决定着随后的对抗原的免疫反应。在健康方面，抗原沿着二条功能路径而越过上皮被吸收。主要路径是降解性地减少了抗原的免疫原性，次要路径可以运输对于特定抗原免疫反应关键的完整的蛋白质。异常的抗原吸收提高了致敏过程(Fargeas等，1995)。
在免疫反应中通过T辅助细胞的细胞因子的产物差别对免疫反应本质有重要的调控效应。天然的免疫反应的细胞因子轮廓决定着随后的特定的免疫反应的表现型。除了控制IgE的合成外，IL-4对于Th2表现型，过敏炎症的特征的发育和成熟是关键的。
这个过程对于发展对摄入的蛋白的耐受性是关键性的。口服耐受性是一种抗原-特异的全身性非反应状态，其特征是局部抗原-特异性的IgA反应。
分离的人肠菌株，乳杆菌菌株GG(Lactobacillns GG，ATCC 53103)最近已表现出提高局部IgA的抗肠道中遇到的饮食的抗原的反应性，因而有助于免疫消除(Isolauri等，1993)。但是还不知道特定的肠细菌菌株是否能直接改变食物抗原的免疫原性，因而抑制过敏反应。
健康肠的微生物群中包括着乳杆菌。假定在肠道中乳杆菌通过与肠粘膜上的病原的微生物竞争受体和营养来起作用。
微生态制剂是活的微生物制品，它通过维持消化道中的天然的微生物群落来提高健康。如果起作用的微生物和它们的行为模式已知，那么可将一种微生物制品认作是一种微生态制剂。这些微生态制剂附着于肠粘膜上，群居于人的肠道，阻止了有害微生物的附着。一个关键的假设是它们到达消化道的粘膜并且在胃肠道的上部不被破坏。乳杆菌GG就是有微生态制剂特性的已知的细菌之一。
本发明者现在已发现胃肠道中的某些细菌，尤其是乳杆菌和有微生态制剂特性的细菌，可用于增强清除饮食的功效，提高口服耐受性，预防和治疗病人的食物引起的过敏性。
此发明的一个方面是用上述的胃肠的细菌进行蛋白水解获得的蛋白水解物也可用于所说的目的。在这里我们表明根据此发明所得的蛋白水解物有提高低变应原性的免疫学效应。此水解物抑制过敏性反应，因而提高消化道免疫障碍机能，即稳定消化道粘膜障碍。
本发明提供了一种改进的蛋白质水解物的配方，这种配方抑制过敏性反应且提高消化道免疫障碍机能。用从微生态制剂的胃肠细菌中获得的酶，尤其是有附着和集居特性以及与那些乳杆菌GG(ATCC 53103)菌株相似的蛋白酶体系的乳杆菌，和胰蛋白酶和/或胃蛋白酶来水解蛋白质，可以获得水解物配方。
另外，本发明的蛋白质水解配方可通过胰蛋白酶和/或胃蛋白酶水解蛋白，且加入到水解物中获得，这样就得到了一种细菌制剂，它包含微生态制剂的胃肠细菌，尤其是有附着和群居特性和与同那些乳杆菌GG菌株(ATCC 53103)相似的蛋白酶体系的乳杆菌。将这些细菌加入到水解物处方中，优选地作为一种冻干的制品。
当对病人用这种一个水解物配方时，期望正在水解的细菌酶在体内释放，借此获得的效果与用以上所定义的改进的水解物配方相同。而且，活的细菌稳定消化道粘膜障碍，增强了局部防御。
本发明的一个实施方案是预防或治疗婴儿由食物引起的过敏反应的一个方法，它包含的步骤对处于危险中的婴儿实施本发明的改进的蛋白质水解物配方，或是实施一种蛋白质水解物的配方，同时用包含微生态制剂的胃肠细菌，尤其是乳杆菌的细菌制品，这种乳杆菌有附着和群居特性，以及同那些菌株乳杆菌GG(ATCC 53103)相似的蛋白酶体系。
本发明的一个进一步实施方案是治疗病人牛奶过敏的一个方法，它包含对病人实施此发明的改进的蛋白质水解物的配方，或是实施一种蛋白质水解物的配方，同时用包含微生态制剂的胃肠细菌，尤其是乳杆菌的细菌制品，这种乳杆菌有附着和群居特性，以及同那些菌株乳杆菌GG(ATCC 53103)相似的蛋白酶体系。
本发明也提供了提高病人对食物抗原耐受原免疫反应的一种方法，这包括对病人口服此发明的改进的蛋白质水解物的配方，或口服一种包含微生态制剂的胃肠细菌，尤其是乳杆菌的细菌制品，这种乳杆菌有附着和群居特性，以及同那些菌株乳杆菌GG(ATCC 53103)相似的蛋白酶体系，或是口服一种蛋白质水解物的配方，同时用包含微生态制剂的胃肠细菌，尤其是乳杆菌的细菌制品，这种乳杆菌有附着和群居特性，以及同那些菌株乳杆菌GG(ATCC53103)相似的蛋白酶体系。
具体地，本发明提供了一种制备用于下调过敏反应和促进消化道免疫屏障的蛋白质水解物配方的方法，它包括以下步骤：用从细菌制剂中得到的酶来水解引起过敏反应的蛋白质和用胃蛋白酶和/或胰蛋白酶来水解引起过敏反应的蛋白质，其中所述细菌制剂包含乳杆菌GG(ATCC 53103)菌株。
此外，本发明还提供了另一种制备用于下调过敏反应和促进消化道免疫屏障的蛋白质水解物配方的方法，它包括以下步骤：用胃蛋白酶和/或胰蛋白酶水解引起过敏反应的蛋白质，并在该水解物中添加一种包含乳杆菌GG(ATCC53103)菌株的细菌制剂。
进一步地，本发明提供了用于下调过敏性反应和促进消化道免疫屏障的蛋白质水解物配方，包括胃蛋白酶和/或胰蛋白酶以及由包括乳杆菌GG(ATCC 53103)菌株的细菌制剂得到的酶的蛋白水解物。该蛋白质水解物配方可以用于制备用于预防或治疗由食物引起的婴儿过敏性反应的配方。另一方面，该蛋白质水解物配方可用于制备用于治疗患者奶过敏的配方。此外，该蛋白质水解物配方可用于制备用于口服给药以提高患者对食物抗原的耐受原免疫反应的配方。
对于本发明第二种方法中所涉及的蛋白质水解物连同包含乳杆菌GG(ATCC 53103)菌株的细菌制剂可以用于制备用于预防和治疗婴儿的由食物引起的过敏性反应的配方。此外，该蛋白质水解物连同包含乳杆菌GG(ATCC53103)菌株的细菌制剂还可以用于制备用于治疗患者奶过敏反应的配方。另一方面，该蛋白质水解物以及包含乳杆菌GG(ATCC 53103)菌株的细菌制剂可以用于制备用于促进患者对食物抗原的耐受原免疫反应的配方。
在本发明以上所定义的方法中，当一种蛋白质水解物的配方与前面所定义的选择好的微生态制剂的细菌结合使用时，这样的配方可以是任何合适的蛋白质水解物配方，已知的或新颖的。它可以是一个部分的蛋白水解物，或是一种彻底的水解的配方。适合于此目的的蛋白质水解物的制备公开于如EP专利申请No.601 802中。
用于此发明的配方和方法中的优选的细菌是乳杆菌GG(ATCC 53103)。
在此说明书和所附的权利要求书中，片语“细菌，尤其是有附着和群居特性，以及同那些菌株乳杆菌GG(ATCC 53103)相似的蛋白酶体系的乳杆菌”应该理解为其附着和群居特性与那些LGG菌株相当的细菌，例如EP专利199 535中定义的。这些细菌也被设想为与LGG有相同的酶体系，这意味着从这种细菌中获得的酶能把蛋白质降解产生水解产物，这与那些从LGG中衍生的酶获得的效果一样。
缩写：
CI 置信区间
IFN-γ 干扰素-γ
IgA 免疫球蛋白A
IgE 免疫球蛋白E
IL-4 白细胞介素-4
LGG 乳杆菌GG(ATCC 53103)
OKT3 抗CD3抗体
PBMC 外周血单核细胞
TNF-α 肿瘤坏死因子-α
WF 受到彻底水解的乳清处方的测试组
WF-GG 受到彻底水解的乳清处方和LGG制品的测试组
P/T-酪蛋白(casein)＝由胃蛋白酶和胰蛋白酶水解的酪蛋白
P/T-αS1-酪蛋白(casein)＝由胃蛋白酶成胰蛋白酶水解的αS1-酪蛋白
图1A-1D：体外由有丝***原引起的PBMCs的增殖反应，分别对于：P/T-酪蛋白(1A)，P/T-αS1-酪蛋白(1B)，用LGG衍生的酶额外水解的P/T-酪蛋白(1C)，用LGG衍生的酶额外水解的P/T-αS1-酪蛋白(1D)。结果表达为对无水解的产物(PHA-RPMI 1640)和有三种浓度(0.1，10和1000微克/毫升)下的水解产物的培养物每分钟的平均计数。水平线代表6个实验的每分钟的几何平均计数，对每一个个体计数相同。
图2：每个患者特应性皮炎的临床值(SCORAD)和其程度中值(A)，强度中值(B)和主观值(C)，以上值是对婴儿在处理前(O)和用彻底水解的乳清处方(WF)或同样的用彻底水解的乳清配方和乳杆菌GG(WF-GG)处理一个月后的值(I)。
图3：酪蛋白和乳杆菌GG降解的酪蛋白对特异反应性的患者(a，b)和在非特异反应性的健康孩子由PBMC的IL-4产物和IFN-γ产物的影响。白柱代表的是在对照培养物中中值细胞因子产物；黑柱代表在含有纯化的酪蛋白的培养物中；阴影柱代表在含有乳杆菌GG降解的酪蛋白的培养物。横切线代表上部和低处的四分位数。
*统计学意义上对比于空白样培养物是显著的双向(pairwise)。
图4：αS1-酪蛋白和乳杆茵GG降解的αS1-酪蛋白对由PBMC的IL-4产物和IFN-γ产物的影响，这是在特异反应性的患者(a，b)和非特异反应性的健康孩子。白柱代表在对照培养物中的中值细胞因子产物；黑柱代表在含有纯化的αS1-酪蛋白的培养物中的；阴影柱代表在含有乳杆菌GG降解的αS1-酪蛋白的培养物中的。横切线代表上部和低部的四分位数(quartiles)。*统计学意义上对比到对照培养物明显的双向
下面的实施例进一步阐明本发明.描述了制备改进的水解物的方法，和本研究中可以观察到表现出良好的治疗效应的实验。
实施例1：用乳杆菌GG获得的酶水解的牛酪蛋白在体外抑制淋巴细胞增殖
1.a.牛奶蛋白的水解
牛的全部酪蛋白和酪蛋白组分(αS1-酪蛋白)从牛奶中提纯(Syvaoja，1992)。用以乳杆菌GG中获取的酶混合物的水解对酪蛋白和αS1-酪蛋白分别进行。用改进的Exterkate和de Veer，1985的方法来分离酶。简而言之，通过对冷冻的细菌细胞超声处理释放出酶。分离出离心的细胞的上层清液，将其用在对酪蛋白和αS1-酪蛋白的水解中，水解于34℃下进行24小时。
如此所得的GG-水解物进一步用胃蛋白酶和胰蛋白酶水解。简单地，样品首先用0.1摩尔/升盐酸中含0.1％的胃蛋白酶溶液在37℃下水解3小时，其溶液pH值为2.5。用250毫克碳酸氢钠和2摩尔/升氢氧化钠调节pH值后，加入0.1％的胰蛋白酶，它们在37℃，pH 8.0下水解5小时。
P/T-酪蛋白和P/T-αS1-酪蛋白样品通过只用胃蛋白酶和胰蛋白酶如上所述那样水解纯化的酪蛋白和αS1-酪蛋白而获得，只是不用GG-水解过程。
1.b.淋巴细胞转化测试
要对有丝***原诱导的淋巴细胞转化的全血液微量法做一个变更。本实验需6至8个健康的自愿者作供血者。简单地，获得肝素抗凝的静脉血液，并用含有抗茵素的RPMI 1640培养介质(Grand Island Biological Co.NY.USA)将其稀释为1∶7。植物凝集素(PHA)(Difco Laboratories，Detroit，Mich.，USA)用含抗菌素的RPMI 1640进行稀释，培养液中其最终的浓度范围是5到1250微克/毫升.酪蛋白和αS1-酪蛋白的冻干水解物用RPMI 1640进行稀释到其最终浓度为0.1微克/毫升(低)，10微克/毫升(中等)和1000微克/毫升(高)，已证明在用伊红的染料排斥研究中对T细胞是无毒的。
采用2套实验研究有丝***原引起的外周血单核细胞(PBMCs)的增殖反应，对于(A)用胃蛋白酶和胰蛋白酶水解的酪蛋白(＝P/T-酪蛋白)，(B)用胃蛋白酶和胰蛋白酶水解的αS1-酪蛋白(＝P/T-αS1-酪蛋白)，(C)另外用乳杆菌GG中获得的酶水解的P/T-酪蛋白，和(D)另外用从乳杆菌GG中获得的酶水解的P/T-αS1-酪蛋白。
实验包含了四种对照培养物，它们是培养介质和有丝***原的不同稀释物，而且相应的测试培养液是三种不同浓度的25微升的水解产物。检测如Sutas等，1996中所描述那样进行。
有丝***原引起的PBMCs增殖反应以扣除本底后每分钟的计数表示。给出对于含125微克/毫升的PHA和RPMI 1640的对照培养液和含有125微克/毫升的PHA及在低、中、高浓度下的水解产物的三个测试培养液的结果。
1.c.统计分析
用一种非参数的配对检验(Wilcoxon signed-rank测试)来对比每个测试培养介质与那些对照培养介质中每分钟计数值的变化。显著水平P＜0.05。根据测试培养介质中每分钟计数值的减少或增大，双向比较的明显结果表示为抑制或刺激作用。
1.d.结果
在用乳杆菌中获得的酶的水解P/T-酪蛋白和P/T-αS1-酪蛋白所做的实验中，同用P/T-酪蛋白和P/T-αS1-酪蛋白(图1A和图1B)相比，在0.1，10和1000微克/毫升(p＝0.03，p＝0.03，和p＝0.03)(图1C和图1D)的有丝***原引致的PBMCs的增殖明显被抑制。
实施例2.用乳胶茵补加的蛋白质水解物配方来治疗有特应性皮炎的婴儿
2.a.患者和研究设计
此研究包含31名婴儿，年龄从2.5到15.7(平均为8)个月，他们符合孩子特异反应性湿疹的Hanifin标准准(Hanifin，1987)。根据特异反应性湿疹他们被归于儿科诊所并被怀疑是牛奶过敏。这种症状的平均开始时间为2.4个月，哺乳期为5.9个月。在第一级亲属中有特异反应性疾病(哮喘，特应性湿疹和过敏性鼻炎)或食物过敏的阳性家族史的有26(占84％)位患者。湿疹病斑用润肤剂和局部的皮质类固醇来处理。但是没有一位患者接受全身性皮质类固醇治疗。除了特应性湿疹外，9位患者(占19％)可发现有胃肠紊乱，如拉稀，呕吐或腹泻。在完成研究期间后，将这些患者进行双盲空白对照剂对照的牛奶刺激实验。只有那些有阳性反应的(27/31)包括于最终的研究人口中。
将这些患者在一个月随机地分为两组。一组(WF，n＝14)接受彻底水解的乳清配方(Valio Ltd，Helsinki，Finland，EP-A-601802)，另一组(WF-GG，n＝13)接受同样的配方，只是其中另有乳杆菌GG制品(5×108cfu/g)(由Valio Ltd，Helsinki，Finland提供)。在用他们指定的配方治疗一个月后，这两组都接受一种彻底水解的乳清配方(Valio Ltd)再额外治疗一个月。在饮食前，测定所有患者的血清总IgE浓度，牛奶特定的IgE(RAST，pharmacia，Uppsala，瑞典)和皮刺试验。用一种市售的牛奶过敏原ALK(Allergologisk Laboratorium，Horsholm，丹麦)和稀释到正常进食浓度测试配方来在前臂手掌面进行皮刺试验。用一个1毫米单峰有钝边小刀以防止较深的刺穿(ALK)，以每毫升10毫克的二盐酸组胺(ALK)作为阳性对照。15分钟后观察反应，如果刺痕的平均直径至少是3毫米，而同时阴性对照仅0毫米，那么将组胺反应尺寸一半或以上的反应记录为阳性。
在实验开始前，一个月后(相当于研究期间)和二个月后，收集粪便样品以测定α-1抗胰蛋白酶和THF-α。
根据由European Task Force对特应性皮炎建立的SCORAD方法(1993)，评价特应性皮炎的严重程度。简单地说，皮炎的程度(score A)用九级规则(ruleof nines)来评估，皮炎的强度(score B)是红斑，浮肿，和/或丘疹、脱皮，地衣化和干燥的单个值的总和。主观值(score C)表现形式(scored 1-10)包括瘙痒和睡眠损失是由父母的评估来确定的。SCORAD由下式计算出：A/5+3.5×B+C
此研究方案得到了Tanpere大学医院伦理检查委员会的批准。征得了婴儿父母的同意。
2.b.粪便样品中α-1抗胰蛋白酶的测定
冷冻的粪便样品在室温下融化并搅匀，取约1克放入玻璃试管中并冻干。将所得的干材料研磨，将50毫克转入一只Eppendorf试管中，加入1毫升0.15M的氯化钠溶液，在一个涡旋混合器中在室温下剧烈混合20分，提取α-1抗胰蛋白酶。所得悬浮液以25,000g离心10分钟除去残渣，将上层清液用于测定α-1抗胰蛋白酶，其使用的是根据制造商说明书的BehringBNA浊度计。结果表示为每克干冻干的粪便中抗胰蛋白酶的毫克数。
2.c粪便样品中TNF-α的测定
深冻的粪便样品在室温下融化，悬浮于1∶1(w/v)的生理盐水中，使其沉淀下来。将0.5-1.0毫升的上层清液转到一Eppendorf试管中在25,000g下离心十分钟，然后，将此上层清液用于测定TNF-α。使用一种商品化的酶免疫分析药盒(Human TNF-α ELISA Kit，Endogen Inc.，Boston，Massachusetts，USA)，如在血清样品所示的那样以测定粪便的TNF-α。
2.d.统计学
因为血清IgE浓度的非对称分布，因而用对数(ln)转变且数据以置信区间(CI)为95％的平均值给出。炎性参数的浓度以较低和较高四分位数的中值给出。将Wilcoxon signed rank测试和Mann-Whitney U-测试用于统计比较中。
2.e.结果
2.e.1：临床资料
平均(95％CI)血清总IgE为31(15-61)kU/l，这是对接受水解物配方的病人而言的。在10/37(37％)的特应性湿疹患者中，牛奶的RAST是阳性的(＞0.4kU/l)。在8/31(30％)的患者中，牛奶的皮刺测试为阳性的。
在开始用药前以及用药1个月后，即研究期间后，每个患者中特应性皮炎的严重性表现于图2中。在用药前，WF组和WF-GG组的中(低四分位数-高四分位数)SCORAD值分别为21(14-31)和26(17-38)且(p＝0.33)。在那些用乳杆菌GG的患者中，一个月后，其SCORAD值有明显的提高(p＝0.008)，但对那些仅用彻底水解的配方而无乳杆菌GG的患者，一个月后，其SCORAD值无明显增加(p＝0.89)。这时，WF组的SCORAD值为19(13-31)，而WF-GG组的SCORAD值为15(7-28)。WF-GG的SCORAD值下降是由于特应性皮炎，程度(score A，p＝0.004)，强度(score B，p＝0.05)和主观值(score C，p＝0.01)的下降(图2)。在WF组中，2个月可以实现SCORAD值的增加，而对WF-GG组在停止施用乳杆菌GG后，SCORAD值保持不变。在2个月时，中(低四分位数-高四分位数)SCORAD值在WF组是14(2-38)而WF-GG组是16(6-25)。
2.e.2.粪便中的α-1抗胰蛋白酶和TNF-α的浓度。
在健康的对照(n＝9)中，α-1抗胰蛋白酶中值(低四分位数-高四分位数)浓度是0.5(0.5-1.7)毫克/克。在施药前，WF组和WF-GG组之间的α-1抗胰蛋白酶浓度是相当的(p＝0.22)。如表1中指示的，在一个月的研究期间中，WF-GG组的α-1抗胰蛋白酶浓度明显下降(p＝0.03)，但WF组中的α-1抗胰蛋白酶浓度却无明显下降(p＝0.68)。在二个月时，α-1抗胰蛋白酶浓度对WF为1.2(0.5-1.6)而WF-GG为0.5(0.5-0.7)。
在健康的对照中，粪便的TNF-α浓度为0(0-0.08)皮克/克。在特异反应性的孩子中，粪便的TNF-α浓度明显较高，P＜0.0001(表1)。施药前，WF组和WF-GG组间TNF-α的浓度是相当的(p＝0.57)。在一个月的研究期间中(表1)，粪便的TNF-α浓度对于WF-GG组明显下降(p＝0.003)，但WF组中不是这样(p＝0.38)。在2个月时WF组的TNF-α浓度下降，而在也施用彻底的水解配方但无乳杆菌GG的WF-GG组，可以测到TNF-α增加的趋势。此时TNF-α的浓度在WF中为84(25-129)而WF-GG中为144(20-338)
表1：在用药前(O)和婴儿接受彻底水解的乳清配方(WF)或还含有乳杆菌GG细菌的配方(WF-GG)一个月后的情况(I)下粪便的α-1抗胰蛋白酶和TNF-α的浓度，数据表示为中值(低四分位数-高四分位数)。
| WF | WF-GG | |
| α-1抗胰蛋白酶 O(mg/g) | 1.7(1.5-2.3) | 1.4(0.5-1.9) |
| α-1 抗胰蛋白酶 I(mg/g) | 1.7(1.1-2.8) | 0.5(0.5-1.0) |
| TNF-α 0(pg/g) | 632(126-1880) | 709(91-1131) |
| TNF-α I(pg/g) | 494(147-1009) | 34(19-103) |
实施例3通过特异反应性孩子中的外周血单核细胞抑制细胞因子产物
3.a.患者和方法
研究了总共有14名年龄为5-29(平均为16)个月的患者，他们符合特应性皮炎的Hanifin标准(Hanifin，1987)，另外有8名年龄相符的非特异反应的健康儿童。在研究期间，他们中没有一人接受全身性的皮质类固醇。
含有腹水流体的OKT3(抗-CD3-抗体)是由芬兰赫尔辛基的赫尔辛基大学的细菌学和免疫学系的M.Kaartinen博士惠赠。如Syvaoja(1992)所叙述的那样，牛的全酪蛋白从牛奶中纯化而来。纯化的酪蛋白是用实施例1中描述的从乳杆菌GG中获得的酶来水解的。将纯化的酪蛋白或乳杆菌GG降解的酪蛋白冻干并贮于室温中。在实验前，它们用RPMI 1640来稀释并且应用过滤消毒装置(0.1μm，Millipore corporation，Bedford，MA，USA)。
完全的培养介质由含有10％的胎牛血清，10mM Hepes缓冲液，2mML-谷氨酰胺(Gibco Life Technologies，Paisley，UK)，50U/ml的青霉素G(Sigma，St.Louis，MO，USA)，10mg/ml庆大霉素(Roussel Laboratories Ltd，Uxbridge，Middlesex，UK)的RPMI 1640所组成。取得5ml的周围静脉血液。含有90％的淋巴样细胞的PBMC用FicollPaque(Pharmacia Biotech，Uppsala，Sweden)梯度离心，并以1×106细胞/毫升悬浮于完全的培养介质中。用含有腹水流体的抗-CD3-抗体以预测定的最佳稀释度预先涂到培养孔上。测试培养液还含有酪蛋白或乳杆菌GG降解的酪蛋白的稀释物，它们的最终浓度为1mg/ml。对纯化的αS1-酪蛋白或乳杆菌GG降解的αS1-酪蛋白，重复以上的实验。在一湿润的含5％的二氧化碳37℃下培养24小时后，收集上层清液，贮于-70℃下以用于细胞因子分析。根据制造商的说明，用商购的ELISA试剂盒来测定培养物上层清液中的IL-4和IFN-γ(IL-4：CLB，Compact Human Interleukin-4 ELISA Kit，Central Laboratory of theNetherlands Red Cross Blood Transfusion Service，Amsterdam，The Netherlands；IFN-γ，EIFNG，Endogen Inc.，Cambridge，MA，USA)。比较于标准曲线，不同途径所得的结果相等，并以皮克/毫升表示。此检测的灵敏度对IL-4为2.3皮克/毫升，而IFN-γ为5皮克/毫升。Wilcoxon signed-rank测定用于统计比较测试培养物和对照培养物。显著性水平为p＜0.05。
3.b.结果
在特异反应性患者中，与对照培养液相比，含有纯化的酪蛋白的培养液中的IL-4和IFN-γ产物均有增加，它们p值分别为0.008和0.008(图3a，b)。当用乳杆菌GG的酶降解时，牛酪蛋白中观察不到这种效应。相反，在含有乳杆菌GG降解的酪蛋白的培养液中，IL-4产物比对照的培养液中的明显减少，p＝0.003(图3a)，而这些培养液中IFN-γ产物与对照培养液中的相当，p＝0.10(图3b)。
在健康的儿童中，含有纯化的酪蛋白的培养液中的IL-4和IFN-γ产物均与对照培养液中的相当，p＝0.10和p＝0.10(图3c，d)。与特异反应性的患者的发现相平行，对健康儿童在含有乳杆菌GG降解的酪蛋白的培养液中，同对照培养液中相比，IL-4产物也明显要少，p＝0.01(图3c)，而这些培养液中IFN-γ产物与对照培养物中的保持相当，p＝0.50(图3d)。用αS1-酪蛋白和乳杆菌降解的αS1-酪蛋白可以获得平行的结果(图4)。
参考文献
关于特应性皮炎的欧洲任务。特应性皮炎的严重性的评估：theSCORAD指标。皮肤病学1993；186：23～31。
Exterkate F和de Veer G.由链球菌cremoris的细胞壁蛋白酶对酪蛋白的不完全分离和降解。实用环境微生物学1985；49：328-32。
Fargeas MJ，Theodorou V，More J，Wal JM，Fioramorti J，Bueno L.在口敏化的豚鼠肠炎后促进的全身性免疫和局部的反应性。胃肠病学1995；109：53-62
Hanifin JM.特应性皮炎的流行病学。过敏反应专论1987；21：116-131
Isolauri E，Majamaa H，Arvola T，Rantala I，Virtanen E，Arvilommi，H.乳杆菌casei菌株GG倒转由乳鼠中牛奶引起的增加的肠的渗透性。胃肠病学1993；105；1643-1650
Majamaa H，Isolauri E.消化道粘膜屏障的评估：有特应性湿疹的儿童中增强的抗原转移的证据。过敏反应临床免疫学杂志1996，在出版中
Majamaa H，Miettinen A，Laine S，Isolauri E.有特应性湿疹的儿童的炎症：粪便嗜伊红的阳离子蛋白质和肿瘤坏死因子作为食物过敏的无损伤的指示物。临床实验过敏反应学1996；26：181-187.Sampson HA，Jame MJ and Bernhisel-Broadbent J.一种从氨基酸中所得的用于有牛奶过敏症的儿童的婴儿配方的安全性 儿科学1992；90：463-465
Sutas Y，Soppi E，Korhonen H，Syvaoja EL，Saxelin M，Rokka T，Isolauri E.用乳杆菌casei GG获得的酶水解牛酪蛋白在体外抑制淋巴细胞的增殖。过敏反应临床免疫学杂志1996，在出版中
Syvaoja EL.定量测定主要的酪蛋白成分和从牛奶中纯化αS2-及k-酪蛋白。Milchwissenschaft 1992；47：563-566。
Claims (9)
1.一种制备用于下调过敏反应和促进消化道免疫屏障的蛋白质水解物配方的方法，它包括以下步骤：用从细菌制剂中得到的酶来水解引起过敏反应的蛋白质和用胃蛋白酶和/或胰蛋白酶来水解引起过敏反应的蛋白质，其中所述细菌制剂包含乳杆菌GG(ATCC 53103)菌株。
2.一种制备用于下调过敏反应和促进消化道免疫屏障的蛋白质水解物配方的方法，它包括以下步骤：
用胃蛋白酶和/或胰蛋白酶水解引起过敏反应的蛋白质，并
在该水解物中添加一种包含乳杆菌GG(ATCC 53103)菌株的细菌制剂。
3.一种用于下调过敏性反应和促进消化道免疫屏障的蛋白质水解物配方，包括胃蛋白酶和/或胰蛋白酶以及由包括乳杆菌GG(ATCC 53103)菌株的细菌制剂得到的酶的蛋白水解物。
4.根据权利要求3所述的蛋白质水解物配方在制备用于预防或治疗由食物引起的婴儿过敏性反应的配方中的用途。
5.根据权利要求3所述的蛋白质水解物配方在制备用于治疗患者牛奶过敏的配方中的用途。
6.根据权利要求3所述的蛋白质水解物配方在制备用于口服给药以提高患者对食物抗原的耐受原免疫反应的配方中的用途。
7.蛋白质水解物连同细菌制剂在制备用于预防和治疗婴儿的由食物引起的过敏性反应的配方中的用途，该细菌制剂包含乳杆菌GG(ATCC 53103)菌株。
8.蛋白质水解物连同细菌制剂在制备用于治疗患者牛奶过敏反应的配方中的用途，该细菌制剂包含乳杆菌GG(ATCC 53103)菌株。
9.蛋白质水解物以及细菌制剂在制备用于促进患者对食物抗原的耐受原免疫反应的配方中的用途，其中所述细菌制剂包括乳杆菌GG(ATCC 53103)菌株。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI952926 | 1995-06-14 | ||
| FI952926A FI104465B (fi) | 1995-06-14 | 1995-06-14 | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1187772A CN1187772A (zh) | 1998-07-15 |
| CN1154506C true CN1154506C (zh) | 2004-06-23 |
Family
ID=8543602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB961947527A Expired - Lifetime CN1154506C (zh) | 1995-06-14 | 1996-06-12 | 预防或治疗过敏的方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6506380B1 (zh) |
| EP (1) | EP0833649B2 (zh) |
| JP (1) | JP3983804B2 (zh) |
| KR (1) | KR100494741B1 (zh) |
| CN (1) | CN1154506C (zh) |
| AR (1) | AR003960A1 (zh) |
| AT (1) | ATE230606T1 (zh) |
| BG (1) | BG63153B1 (zh) |
| BR (1) | BR9607827A (zh) |
| CA (1) | CA2224320C (zh) |
| CZ (1) | CZ291904B6 (zh) |
| DE (1) | DE69625690T3 (zh) |
| DK (1) | DK0833649T4 (zh) |
| EE (1) | EE03424B1 (zh) |
| ES (1) | ES2191103T5 (zh) |
| FI (1) | FI104465B (zh) |
| HK (1) | HK1010081A1 (zh) |
| IL (1) | IL122577A0 (zh) |
| MX (1) | MX9710109A (zh) |
| MY (1) | MY113912A (zh) |
| NO (1) | NO321504B1 (zh) |
| NZ (1) | NZ310478A (zh) |
| PL (1) | PL185123B1 (zh) |
| RO (1) | RO120243B1 (zh) |
| SK (1) | SK284245B6 (zh) |
| WO (1) | WO1997000078A1 (zh) |
| ZA (1) | ZA965088B (zh) |
Families Citing this family (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| EP0986314B1 (en) * | 1997-06-03 | 2008-09-10 | Ganeden Biotech, Inc. | Probiotic lactic acid bacterium to treat bacterial infections associated with sids |
| IL138002A0 (en) | 1999-01-19 | 2001-10-31 | Maxygen Inc | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| CA2378426C (en) | 1999-08-05 | 2010-03-23 | Societe Des Produits Nestle S.A. | Bifidobacteria capable of preventing diarrhea |
| TR200200301T2 (tr) | 1999-08-05 | 2004-12-21 | Societe Des Produits Nestle S.A. | Patojenik bakterilerin sebep olduğu ishali ölemeye elverişli bifidobakteriler |
| WO2001057534A2 (en) * | 2000-02-04 | 2001-08-09 | Bioseek | Compositions and methods for reducing autoimmunity |
| FI110668B (fi) | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
| MXPA03001673A (es) * | 2000-09-25 | 2003-06-09 | Nestle Sa | Bacteria de acido lactico capaz de reducir una tendencia individual a desarrollar reacciones alergicas. |
| EP1593382A1 (en) | 2000-10-06 | 2005-11-09 | Société des Produits Nestlé S.A. | Use of probiotic lactic bacteria for balancing the skin's immune system |
| FI109602B (fi) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
| EP1228707A1 (en) * | 2001-02-01 | 2002-08-07 | Campina Melkunie B.V. | Use of alpha-lactalbumin as prebiotic agent |
| CA2439078C (en) * | 2001-03-09 | 2009-08-25 | Societe Des Produits Nestle S.A. | Composition improving age-related physiological deficits and increasing longevity |
| JP2003137804A (ja) * | 2001-10-31 | 2003-05-14 | Morinaga Milk Ind Co Ltd | インターロイキン−１８誘導剤 |
| EP1364586A1 (en) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
| JP4376180B2 (ja) | 2002-06-04 | 2009-12-02 | ディーエスエム アイピー アセッツ ビー．ブイ． | トリペプチドに富むタンパク水解物 |
| ATE402993T1 (de) | 2002-06-28 | 2008-08-15 | Puleva Biotech Sa | Probiotische stämme, verfahren zur ihren selektion, diese enthaltende zusammensetzungen und ihre verwendung |
| EP1384483A1 (en) | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
| US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
| US20040208863A1 (en) * | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
| CN1863463B (zh) | 2003-06-23 | 2011-05-04 | 雀巢技术公司 | 用于促进肠道屏障成熟的营养组合物 |
| CA2556736C (en) | 2004-02-25 | 2013-02-19 | Pioneer Hi-Bred International, Inc. | Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof |
| US20050265946A1 (en) * | 2004-05-28 | 2005-12-01 | Kao Corporation | Elastase inhibitor |
| US7862808B2 (en) | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
| MX2007012697A (es) | 2005-04-13 | 2008-01-14 | Nestec Sa | Formula para infantes con probioticos. |
| US7303745B2 (en) | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
| US20060233762A1 (en) * | 2005-04-15 | 2006-10-19 | Mcmahon Robert J | Method for treating or preventing systemic inflammation in formula-fed infants |
| BRPI0618569A2 (pt) * | 2005-11-14 | 2011-09-06 | Nestec Sa | promoção de toleráncia oral com proteìnas glicadas |
| CN101420965B (zh) | 2006-02-15 | 2013-08-07 | 雀巢产品技术援助有限公司 | 长双歧杆菌在制备预防和治疗炎症的药物中的用途 |
| MY149913A (en) | 2006-03-07 | 2013-10-31 | Nestec Sa | Synbiotic mixture |
| BRPI0713596A2 (pt) * | 2006-06-15 | 2012-10-30 | Nestec Sa | indução de toleráncia às proteìnas do ovo |
| RU2468808C2 (ru) * | 2007-02-28 | 2012-12-10 | Мид Джонсон Нутришен Компани | Способ лечения или предотвращения системного воспаления |
| EP1974735A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Reduction of risk of diarrhoea |
| CN101273738B (zh) * | 2007-03-28 | 2011-06-01 | 哈尔滨正方科技有限公司 | 在常温下保持高活菌数的调配型酸性乳饮料的制备方法 |
| EP1974743A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics to Improve Gut Microbiota |
| EP1974734A1 (en) † | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
| US7977078B2 (en) | 2007-08-24 | 2011-07-12 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
| EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
| CA2712207A1 (en) | 2008-01-24 | 2009-07-30 | Nestec S.A. | Capsule containing nutritional ingredients and method of delivery of a nutritional liquid from the capsule |
| DK2244734T3 (en) | 2008-02-01 | 2016-08-15 | Murdoch Childrens Res Inst | PROCEDURE FOR INDUCTION OF TOLERANCE ABOUT AN ALLERGY |
| PT2265135T (pt) | 2008-03-14 | 2018-02-21 | Nestec Sa | Mistura simbiótica |
| EP2127661A1 (en) | 2008-05-27 | 2009-12-02 | Nestec S.A. | Probiotics to improve gut microbiotica |
| ES2575005T3 (es) | 2008-06-13 | 2016-06-23 | Codexis, Inc. | Método de síntesis de variantes de polinucleótidos |
| US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| MX2010014500A (es) | 2008-06-24 | 2011-05-30 | Codexis Inc | Procedimientos biocataliticos para la preparacion de compuestos de prolina biciclica fusionada sustancialmente estereomericamente puros. |
| EP2147678A1 (en) | 2008-07-21 | 2010-01-27 | Nestec S.A. | Probiotics to increase IgA secretion in infants born by caesarean section |
| US8426178B2 (en) | 2008-08-27 | 2013-04-23 | Codexis, Inc. | Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| SG172891A1 (en) | 2009-01-08 | 2011-08-29 | Codexis Inc | Transaminase polypeptides |
| WO2010107644A2 (en) | 2009-03-17 | 2010-09-23 | Codexis, Inc. | Variant endoglucanases and related polynucleotides |
| BRPI1010239A2 (pt) | 2009-03-31 | 2016-10-11 | Codexis Inc | endoglucanases aprimoradas, derivados e seus usos |
| CA2762616C (en) | 2009-06-16 | 2015-08-18 | Codexis, Inc. | Beta-glucosidase variant enzymes and related polynucleotides |
| CN102482648B (zh) | 2009-06-22 | 2014-12-10 | 科德克希思公司 | 酮还原酶介导的产生α氯代醇的立体选择性途径 |
| WO2011011630A2 (en) | 2009-07-23 | 2011-01-27 | Codexis, Inc. | Nitrilase biocatalysts |
| IN2012DN00878A (zh) * | 2009-08-18 | 2015-05-22 | Nestec Sa | |
| MX341971B (es) * | 2009-08-18 | 2016-09-08 | Nestec Sa | Una composicion nutricional que comprende cepas de bifidobacterium longum y que reduce los sintomas de la alergia a los alimentos, especialmente en lactantes y niños. |
| WO2011022548A2 (en) | 2009-08-19 | 2011-02-24 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
| US8785170B2 (en) | 2009-09-04 | 2014-07-22 | Codexis, Inc. | Variant CBH2 cellulases and related polynucleotides |
| EP2295535A1 (en) * | 2009-09-11 | 2011-03-16 | Mead Johnson Nutrition Company | Probiotic material |
| EP2478137B1 (en) | 2009-09-18 | 2017-09-13 | Codexis, Inc. | Reduced codon mutagenesis |
| CA2781399C (en) | 2009-11-25 | 2015-01-20 | Codexis, Inc. | Recombinant thermoascus aurantiacus beta-glucosidase variants for production of fermentable sugars from cellulosic biomass |
| WO2011066457A2 (en) | 2009-11-25 | 2011-06-03 | Codexis, Inc. | Recombinant beta-glucosidase variants for production of soluble sugars from cellulosic biomass |
| AU2010329990B2 (en) | 2009-12-08 | 2015-07-16 | Nestec S.A. | Infant formula with probiotics and milk fat globule membrane components |
| CN102884178B (zh) | 2009-12-08 | 2014-12-03 | 科德克希思公司 | 拉唑化合物的合成 |
| MX2012007681A (es) | 2009-12-31 | 2013-01-29 | Pioneer Hi Bred Int | Ingenieria de resistencia de plantas a enfermedades causadas por patogenos. |
| EP2566497B1 (en) | 2010-05-04 | 2015-07-29 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
| JP2013528374A (ja) | 2010-05-10 | 2013-07-11 | パーシード セラピューティクス リミテッド ライアビリティ カンパニー | Ｖｌａ４のポリペプチド阻害剤 |
| CA2798937A1 (en) | 2010-05-28 | 2011-12-01 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| EP2582799B1 (en) | 2010-06-17 | 2017-12-20 | Codexis, Inc. | Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol |
| CA2804019A1 (en) | 2010-06-28 | 2012-01-12 | Codexis, Inc. | Fatty alcohol forming acyl reductases (fars) and methods of use thereof |
| WO2012003299A2 (en) | 2010-06-30 | 2012-01-05 | Codexis, Inc. | Highly stable beta-class carbonic anhydrases useful in carbon capture systems |
| US9006460B2 (en) | 2010-08-16 | 2015-04-14 | Cardiome International Ag | Process for preparing aminocyclohexyl ether compounds |
| EP2606131B1 (en) | 2010-08-20 | 2017-03-08 | Codexis, Inc. | Use of glycoside hydrolase 61 family proteins in processing of cellulose |
| HUE037616T2 (hu) | 2010-12-08 | 2018-09-28 | Codexis Inc | Biokatalizátorok és eljárások armodafinil szintéziséhez |
| EE05750B1 (et) | 2011-02-25 | 2015-06-15 | OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isoleeritud mikroorganismi tüvi Lactobacillus gasseri MCC2 DSM 23882 ning selle kasutamine |
| EP2691517A4 (en) | 2011-03-30 | 2015-04-22 | Codexis Inc | FERMENTATION OF PENTOSES BY A RECOMBINANT MICROORGANISM |
| US9102963B2 (en) | 2011-04-13 | 2015-08-11 | Codexis, Inc. | Biocatalytic process for preparing eslicarbazepine and analogs thereof |
| UA111078C2 (uk) * | 2011-05-03 | 2016-03-25 | Нестек С.А. | Гідролізат білкового субстрату і спосіб його виготовлення |
| US8778652B2 (en) | 2011-06-30 | 2014-07-15 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| DK2748317T3 (en) | 2011-08-22 | 2017-07-17 | Codexis Inc | GH61 glycoside hydrolase protein variants and cofactors that enhance GH61 activity |
| WO2013036861A1 (en) | 2011-09-08 | 2013-03-14 | Codexis, Inc | Biocatalysts and methods for the synthesis of substituted lactams |
| WO2013048661A1 (en) | 2011-09-30 | 2013-04-04 | Codexis, Inc. | Fungal proteases |
| WO2013052101A1 (en) * | 2011-10-03 | 2013-04-11 | Kelly Foods Corporation | Probiotic composition for pets and method of providing the same |
| US20130089638A1 (en) * | 2011-10-11 | 2013-04-11 | Mead Johnson Nutrition Company | Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes |
| WO2013074650A1 (en) | 2011-11-18 | 2013-05-23 | Codexis, Inc. | Biocatalysts for the preparation of hydroxy substituted carbamates |
| WO2013096244A1 (en) | 2011-12-20 | 2013-06-27 | Codexis, Inc. | Endoglucanase 1b (eg1b) variants |
| SG11201405990PA (en) | 2012-03-23 | 2014-11-27 | Codexis Inc | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs |
| US20130251829A1 (en) * | 2012-03-23 | 2013-09-26 | Mead Johnson Nutrition Company | Probiotic derived non-viable material for infection prevention and treatment |
| HUE042605T2 (hu) | 2012-05-08 | 2019-07-29 | Codexis Inc | Biokatalizátorok és kémiai vegyületek hidroxilálására szolgáló eljárások |
| WO2013170050A1 (en) | 2012-05-11 | 2013-11-14 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| WO2013188313A2 (en) | 2012-06-11 | 2013-12-19 | Codexis, Inc. | Fungal xylanases and xylosidases |
| AU2013348272A1 (en) | 2012-11-20 | 2015-05-14 | Shell Internationale Research Maatschappij B.V. | Pentose fermentation by a recombinant microorganism |
| EP2928865B1 (en) | 2012-12-07 | 2018-04-11 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| JP6618180B2 (ja) | 2012-12-21 | 2019-12-11 | コデクシス， インコーポレイテッド | キラルアミンを合成するための操作された生体触媒および方法 |
| CA2898495C (en) | 2013-01-18 | 2021-06-01 | Codexis, Inc. | Engineered biocatalysts useful for carbapenem synthesis |
| SI2961844T1 (sl) | 2013-02-28 | 2018-11-30 | Codexis, Inc. | Spremenjeni polipeptidi transaminaze za industrijsko biokatalizo |
| CN103355405A (zh) * | 2013-04-07 | 2013-10-23 | 苏州旭优食品科技有限公司 | 一种低过敏性含乳制品的加工工艺 |
| HUE055899T2 (hu) | 2013-04-18 | 2022-01-28 | Codexis Inc | Átszerkesztett fenilalanin-ammónia-liáz polipeptidek |
| HUE053379T2 (hu) | 2013-11-13 | 2021-06-28 | Codexis Inc | Génmódosított imin-reduktázok és eljárások keton és amin vegyületek reduktív aminálására |
| DK3145536T3 (da) | 2014-04-16 | 2022-01-03 | Codexis Inc | Modificeret tyrosinammoniaklyase |
| US9708587B2 (en) | 2014-07-09 | 2017-07-18 | Codexis, Inc. | P450-BM3 variants with improved activity |
| HUE053363T2 (hu) | 2014-11-25 | 2021-06-28 | Codexis Inc | Módosított iminreduktázok és eljárások keton- és aminvegyületek reduktív aminálására |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| HUE062016T2 (hu) | 2014-12-22 | 2023-09-28 | Codexis Inc | Humán alfa-galaktozidáz variánsok |
| ES2830725T3 (es) | 2015-02-10 | 2021-06-04 | Codexis Inc | Polipéptidos cetoreductasa para la síntesis de compuestos quirales |
| DK3292136T3 (da) | 2015-05-07 | 2021-03-22 | Codexis Inc | Penicillin-g-acylaser |
| WO2017007547A1 (en) | 2015-07-07 | 2017-01-12 | Codexis, Inc. | Novel p450-bm3 variants with improved activity |
| AU2017260355B2 (en) | 2016-05-05 | 2023-03-30 | Codexis, Inc. | Penicillin-G acylases |
| EP3469088B1 (en) | 2016-06-09 | 2023-09-06 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
| CA3027189A1 (en) | 2016-06-15 | 2017-12-21 | Codexis, Inc. | Engineered beta-glucosidases and glucosylation methods |
| IL264686B2 (en) | 2016-08-26 | 2024-07-01 | Codexis Inc | Engineered imine reductases and methods for reversible amination of ketone and amine compounds |
| WO2018129130A1 (en) | 2017-01-05 | 2018-07-12 | Codexis, Inc. | Penicillin-g acylases |
| US20180223264A1 (en) | 2017-02-03 | 2018-08-09 | Codexis, Inc. | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
| EP3579867A4 (en) | 2017-02-13 | 2021-03-10 | Codexis, Inc. | MANIPULATED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES |
| SG11201909807TA (en) | 2017-04-24 | 2019-11-28 | Tesaro Inc | Methods of manufacturing of niraparib |
| CN110831618B (zh) | 2017-04-27 | 2023-08-25 | 科德克希思公司 | 酮还原酶多肽及多核苷酸 |
| JP7401902B2 (ja) | 2017-05-08 | 2023-12-20 | コデクシス， インコーポレイテッド | 遺伝子操作されたリガーゼバリアント |
| WO2018231462A1 (en) | 2017-06-14 | 2018-12-20 | Codexis, Inc. | Engineered transaminase polypeptides for industrial biocatalysis |
| WO2019005337A1 (en) | 2017-06-27 | 2019-01-03 | Codexis, Inc. | PENICILLIN G ACYLASES |
| KR20200023455A (ko) | 2017-06-30 | 2020-03-04 | 코덱시스, 인코포레이티드 | T7 rna 폴리머라제 변이체 |
| US10738286B2 (en) | 2017-06-30 | 2020-08-11 | Codexis, Inc. | T7 RNA polymerase variants |
| WO2019094301A1 (en) | 2017-11-07 | 2019-05-16 | Codexis, Inc. | Transglutaminase variants |
| US11535833B2 (en) | 2017-12-13 | 2022-12-27 | Glaxosmithkline Intellectual Property Development Limited | Carboxyesterase biocatalysts |
| SG11202004185PA (en) | 2017-12-13 | 2020-06-29 | Codexis Inc | Carboxyesterase polypeptides for amide coupling |
| CA3102968A1 (en) | 2018-06-12 | 2019-12-19 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| KR20210031933A (ko) | 2018-07-09 | 2021-03-23 | 코덱시스, 인코포레이티드 | 조작된 포스포펜토뮤타제 변이체 효소 |
| WO2020014047A1 (en) | 2018-07-09 | 2020-01-16 | Codexis, Inc. | Engineered purine nucleoside phosphorylase variant enzymes |
| EP3821015A4 (en) | 2018-07-09 | 2022-07-13 | Codexis, Inc. | DEOXYRIBOSE-PHOSPHATE MODIFIED ALDOLASES |
| KR20210030379A (ko) | 2018-07-09 | 2021-03-17 | 코덱시스, 인코포레이티드 | 조작된 갈락토스 옥시다제 변이 효소 |
| CN112673091A (zh) | 2018-07-09 | 2021-04-16 | 科德克希思公司 | 工程化泛酸激酶变体酶 |
| EP3820833A4 (en) | 2018-07-12 | 2022-08-03 | Codexis, Inc. | MODIFIED AMMONIA-LYASE PHENYLALANINE POLYPEPTIDES |
| WO2020028039A1 (en) | 2018-07-30 | 2020-02-06 | Codexis, Inc. | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
| EP3874033A4 (en) | 2018-10-29 | 2022-08-03 | Codexis, Inc. | MANIPULATED VARIANTS OF DNA POLYMERASE |
| CA3122524A1 (en) | 2018-12-14 | 2020-06-18 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| EA202191735A1 (ru) | 2018-12-20 | 2021-11-24 | Кодексис, Инк. | Варианты альфа-галактозидазы человека |
| EP4003061B1 (en) | 2019-07-23 | 2024-04-24 | FrieslandCampina Nederland B.V. | Nutritional composition comprising milk fat and immunoglobulin |
| KR20220106738A (ko) | 2019-08-30 | 2022-07-29 | 코덱시스, 인코포레이티드 | 조작된 리파제 변이체 |
| JP2022547523A (ja) | 2019-09-12 | 2022-11-14 | コデクシス， インコーポレイテッド | １０－アセチル－３，７－ジヒドロキシフェノキサジンに対するペルオキシダーゼ活性 |
| US20220372542A1 (en) | 2019-10-02 | 2022-11-24 | Abbott Diabetes Care Inc. | Detection of analytes by protein switches |
| AU2020408066A1 (en) | 2019-12-20 | 2022-06-30 | Codexis, Inc. | Engineered acid alpha-glucosidase variants |
| IL296841A (en) | 2020-04-10 | 2022-11-01 | Codexis Inc | Transaminase transaminase polypeptides |
| BR112023003606A2 (pt) | 2020-08-28 | 2023-03-28 | Codexis Inc | Protease recombinante, composição, sequência polinucleotídica recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma protease recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso |
| JP2023539634A (ja) | 2020-08-28 | 2023-09-15 | コデクシス， インコーポレイテッド | 操作されたアミラーゼバリアント |
| US20220186231A1 (en) | 2020-12-11 | 2022-06-16 | Willow Biosciences, Inc. | Recombinant acyl activating enzyme (aae) genes for enhanced biosynthesis of cannabinoids and cannabinoid precursors |
| US11898174B2 (en) | 2020-12-18 | 2024-02-13 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
| CA3214973A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered guanylate kinase variant enzymes |
| CA3214972A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered adenylate kinase variant enzymes |
| CA3215105A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered acetate kinase variant enzymes |
| EP4314264A1 (en) | 2021-04-02 | 2024-02-07 | Codexis, Inc. | Engineered cyclic gmp-amp synthase (cgas) variant enzymes |
| CA3227215A1 (en) | 2021-07-30 | 2023-02-02 | Trish Choudhary | Recombinant prenyltransferase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| WO2023023621A1 (en) | 2021-08-19 | 2023-02-23 | Willow Biosciences, Inc. | Recombinant olivetolic acid cyclase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| WO2023069921A1 (en) | 2021-10-19 | 2023-04-27 | Epimeron Usa, Inc. | Recombinant thca synthase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| WO2024040020A1 (en) | 2022-08-15 | 2024-02-22 | Absci Corporation | Quantitative affinity activity specific cell enrichment |
| WO2024150146A1 (en) | 2023-01-12 | 2024-07-18 | Novartis Ag | Engineered ketoreductase polypeptides |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3886288A (en) * | 1970-06-15 | 1975-05-27 | Swift & Co | Cheese manufacture using highly active proteolytic enzymes |
| JPS5279086A (en) | 1975-12-25 | 1977-07-02 | Nippon Soda Co Ltd | Preparation of antibiotic tunicamycin |
| JPS5279083A (en) * | 1975-12-26 | 1977-07-02 | Morinaga Milk Industry Co Ltd | Production of protein decomposed substance not having bitterness and antigen property |
| JPS6041751B2 (ja) | 1976-06-22 | 1985-09-18 | ジエコ−株式会社 | デジタル電子時計 |
| JPS548785A (en) | 1977-06-21 | 1979-01-23 | Kikkoman Corp | Preparation of protein hydrolyzate |
| US4839281A (en) † | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| DK589785A (da) * | 1985-12-18 | 1987-06-19 | Samuelsson Ernst Gunnar | Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet |
| ATE84680T1 (de) † | 1987-12-23 | 1993-02-15 | Nestle Sa | Verfahren zur herstellung eines molkeeiweisshydrolysates und eines hypoallergenen nahrungsmittels. |
| DD281540A5 (de) * | 1988-08-08 | 1990-08-15 | Berlin Chemie Veb | Verfahren zur herstellung von nutritiva |
| ATE113441T1 (de) † | 1989-10-02 | 1994-11-15 | Sandoz Nutrition Ltd | Proteinhydrolysaten. |
| JP3071877B2 (ja) † | 1991-06-27 | 2000-07-31 | 財団法人糧食研究会 | 経口寛容誘導能を有する低アレルゲン性酵素分解ペプチド組成物 |
| US5952034A (en) * | 1991-10-12 | 1999-09-14 | The Regents Of The University Of California | Increasing the digestibility of food proteins by thioredoxin reduction |
| ES2111625T3 (es) * | 1992-07-06 | 1998-03-16 | Nestle Sa | Agente antigastritis. |
| FI94089C (fi) | 1992-12-10 | 1995-07-25 | Valio Oy | Menetelmä allergiaa aiheuttavien yhdisteiden poistamiseksi proteiinipitoisista koostumuksista |
| RU2031586C1 (ru) | 1993-02-05 | 1995-03-27 | Тамара Георгиевна Извекова | Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения |
| GB9312369D0 (en) | 1993-06-16 | 1993-07-28 | Sandoz Nutrition Ltd | Organic compounds |
| WO1995014485A1 (fr) † | 1993-11-23 | 1995-06-01 | Kabushiki Kaisha Wado Doctors Group | Composition adjuvante de flore intestinale et appareil et systeme de production |
| FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
-
1995
- 1995-06-14 FI FI952926A patent/FI104465B/fi not_active IP Right Cessation
-
1996
- 1996-06-11 MY MYPI96002357A patent/MY113912A/en unknown
- 1996-06-12 US US08/973,963 patent/US6506380B1/en not_active Expired - Lifetime
- 1996-06-12 BR BR9607827-8A patent/BR9607827A/pt not_active Application Discontinuation
- 1996-06-12 EP EP96918707A patent/EP0833649B2/en not_active Expired - Lifetime
- 1996-06-12 DE DE69625690T patent/DE69625690T3/de not_active Expired - Lifetime
- 1996-06-12 KR KR1019970709383A patent/KR100494741B1/ko not_active IP Right Cessation
- 1996-06-12 CA CA2224320A patent/CA2224320C/en not_active Expired - Lifetime
- 1996-06-12 SK SK1715-97A patent/SK284245B6/sk not_active IP Right Cessation
- 1996-06-12 DK DK96918707T patent/DK0833649T4/da active
- 1996-06-12 EE EE9700339A patent/EE03424B1/xx unknown
- 1996-06-12 AT AT96918707T patent/ATE230606T1/de active
- 1996-06-12 CN CNB961947527A patent/CN1154506C/zh not_active Expired - Lifetime
- 1996-06-12 ES ES96918707T patent/ES2191103T5/es not_active Expired - Lifetime
- 1996-06-12 JP JP50267197A patent/JP3983804B2/ja not_active Expired - Lifetime
- 1996-06-12 RO RO97-02328A patent/RO120243B1/ro unknown
- 1996-06-12 WO PCT/FI1996/000350 patent/WO1997000078A1/en not_active Application Discontinuation
- 1996-06-12 CZ CZ19973997A patent/CZ291904B6/cs not_active IP Right Cessation
- 1996-06-12 IL IL12257796A patent/IL122577A0/xx not_active IP Right Cessation
- 1996-06-12 PL PL96324010A patent/PL185123B1/pl unknown
- 1996-06-12 NZ NZ310478A patent/NZ310478A/xx not_active IP Right Cessation
- 1996-06-13 AR ARP960103134A patent/AR003960A1/es unknown
- 1996-06-14 ZA ZA965088A patent/ZA965088B/xx unknown
-
1997
- 1997-12-11 NO NO19975832A patent/NO321504B1/no not_active IP Right Cessation
- 1997-12-11 MX MX9710109A patent/MX9710109A/es unknown
- 1997-12-23 BG BG102144A patent/BG63153B1/bg unknown
-
1998
- 1998-09-24 HK HK98110938A patent/HK1010081A1/xx not_active IP Right Cessation
-
2002
- 2002-12-18 US US10/321,661 patent/US7172756B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1154506C (zh) | 预防或治疗过敏的方法 | |
| Majamaa et al. | Probiotics: a novel approach in the management of food allergy | |
| Brouwer et al. | No effects of probiotics on atopic dermatitis in infancy: a randomized placebo‐controlled trial | |
| HØST et al. | A prospective study of cow's milk allergy in exclusively breast‐fed infants: incidence, pathogenetic role of early inadvertent exposure to cow's milk formula, and characterization of bovine milk protein in human milk | |
| RU2539514C2 (ru) | Питательная композиция, содержащая штаммы bifidobacterium longum и ослабляющая сиптомы пищевой аллергии, особенно у младенцев и детей | |
| European Society for Paediatric Gastroenterology and Nutrition Working Group for the Diagnostic Criteria for Food Allergy | Diagnostic criteria for food allergy with predominantly intestinal symptoms | |
| CN1942197A (zh) | 用于改进母乳哺育以减少过敏反应危险性的方法 | |
| Kazemi et al. | Allergenicity reduction of bovine milk β-lactoglobulin by proteolytic activity of lactococcus lactis BMC12C and BMC19H isolated from Iranian dairy products | |
| RU2522282C2 (ru) | Применение штамма вifidobacterium для получения композиции, предназначенной для профилактики и/или лечения проявлений аллергического типа | |
| US20170368113A1 (en) | Use of a hyperimmune egg product to prevent and treat dysbiosis | |
| Cave et al. | Evaluation of the immunogenicity of dietary proteins in cats and the influence of the canning process | |
| RU2174012C2 (ru) | Способы профилактики или лечения аллергии | |
| Crane | Pro and anti: the biotics of allergic disease | |
| AU710126C (en) | Methods of preventing or treating allergies | |
| Ferguson | Immunological response to food | |
| Kh et al. | A Topic Dermatitis and Gastrointestinal Diseases | |
| Solieva et al. | GENERAL PRINCIPLES OF DIAGNOSIS AND TREATMENT OF FOOD ALLERGY IN CHILDREN AT DIFFERENT AGE PERIODS | |
| Wright | Immunology of food intolerance in adults | |
| WRIGHT | Block, Southampton General Hospital, Southampton SO9 qXY | |
| Sabra et al. | Score for the diagnosis of food allergy | |
| Wang et al. | Immunomodulatory Effects of Lactic Acid Bacteria in Patients with Perennial Allergic Rhinitis | |
| Docena et al. | G. zyxwvutsrqponmlkj |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1046586 Country of ref document: HK |
|
| CX01 | Expiry of patent term |
Granted publication date: 20040623 |
|
| EXPY | Termination of patent right or utility model |